ClinicalTrials.gg
CompletedNCT02061540CAMEOUpdated Mar 29, 2019Results posted

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

A Phase 2 interventional study of LUM001 in Primary Sclerosing Cholangitis (PSC), sponsored by Mirum Pharmaceuticals, Inc.. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Enrollment
29th of 57
27 · median 27
Started
2014
with 1 other
Phase 2
26 of 75
6 open now
Registered
21st of 75
by date
Lead sponsor
3 of 75
Mirum Pharmaceuticals, Inc.

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 29th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2014, is one of 26 in phase 2, and was the 21st registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

The study is an open-label study in adults with primary sclerosing cholangitis to evaluate the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.

03

Conditions studied

  • Primary Sclerosing Cholangitis (PSC)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between the ages of 18-80 years, inclusive.
  2. Diagnosis of PSC
  3. If inflammatory bowel disease (IBD) is present, disease activity ≤ 2 (normal to moderate), using the physician assessment on the Mayo ulcerative colitis (UC) disease activity score.
  4. Patients receiving azathioprine for intestinal bowel disease are eligible to participate in the study provided that they have had no IBD exacerbations for at least 6 months.
  5. Females of must have a negative serum pregnancy test [β human chorionic gonadotropin (β-hCG)] during screening and negative urine pregnancy test at the baseline/Day 0 visit.
  6. Sexually active females must be , surgically sterile, or if premenopausal, be prepared to use an effective method (≤ 1% failure rate) of during the trial.
  7. Ability to read and understand English in order to use the study-related questionnaires and the text on the eDiary screen.
  8. Must be willing and able to use an eDiary daily for a minimum of 20 weeks.
  9. Must digitally accept the licensing agreement in the eDiary software at the outset of the study.
  10. Must complete at least 10 eDiary Adult ItchRO reports (AM or PM) during each of two consecutive weeks of the screening period prior to allocation to treatment (maximum possible reports = 14 per week).
  11. Access to phone for scheduled calls from study site.
  12. Must agree to comply with the study protocol procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Small duct PSC (clinical biochemical and histological features compatible with PSC, but having a normal cholangiogram).
  2. Presence of a dominant stricture unless brushings and/or of the stricture are negative for dysplasia or within 6 months of screening.
  3. Surgical or endoscopic biliary tree interventions for treatment of strictures within 6 months of screening.
  4. IBD flare (Mayo UC disease activity score > 5 including endoscopic evaluation) within 3 months prior to screening.
  5. Secondary cause of sclerosing cholangitis (e.g., choledocholithiasis, post-surgical biliary stricture, intra-arterial chemotherapy, recurrent pancreatitis, IgG4 associated cholangiopathy, AIDS cholangiopathy).
  6. or ALT ≥ 5 x at screening.
  7. History or presence of any other concomitant significant liver disease as assessed by the Investigator.
  8. Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease).
  9. Known history of (HIV) infection.
  10. The anticipated need for a surgical procedure within 20 weeks from randomization.
  11. Any female who is pregnant or lactating or who is planning to become pregnant within 20 weeks of randomization.
  12. History of cancer, except for basal or squamous cell carcinoma of the skin, or with any laboratory or physical exam or diagnostic procedure finding suggestive of current malignancy.
  13. Family history of any documented hereditary cancer syndrome.
  14. History of alcohol or other substance abuse within 1 year prior to screening.
  15. Receipt of an drug, biologic, or medical device within 30 days prior to Screening, or 5 half-lives of the study agent, whichever is longer.
  16. History of noncompliance with medical regimens, unreliability, mental instability or incompetence that could compromise the validity of or lead to noncompliance with the study protocol.
  17. Any other conditions or abnormalities which, in the opinion of the Investigator or Medical Monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    LUM001

    LUM001 administered orally once each day

    Drug: LUM001

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was defined as any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. TEAEs were AEs with a start date on or after the first dose of investigational product and started prior to the last dose of investigational product plus 14 days.

    Time frame: From start of study drug administration until Week 18

  2. Change From Baseline in Fasting Serum Bile Acid Level at Week 14

    Serum bile acid levels were evaluated using blood samples collected.

    Time frame: Baseline, Week 14

Secondary outcomes

  1. Change From Baseline in Liver Enzyme Levels in Serum

    Levels of liver enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) in serum were evaluated.

    Time frame: Baseline, Week 14

  2. Change From Baseline in Bilirubin Levels at Week 14

    Total Bilirubin and Direct (Conjugated) Bilirubin levels were evaluated.

    Time frame: Baseline, Week 14

  3. Change From Baseline in Pruritus as Measured by Adult Itch Reported Outcome (ItchRO) Weekly Sum Score

    The Adult ItchRO instrument was completed twice daily using an electronic diary (eDiary). Each morning and evening score had a range from 0-10, with the higher score indicating increasing itch severity. The following was used for assessing the Adult ItchRO daily score: The score which represented the most severe itching for the day (morning or evening) was taken for each day as the daily score (maximum daily score of 10); If only 1 of the 2 scores was available for the day, the score that was available was used as the daily score; If both the morning and the evening scores were missing, the score was considered missing for the day.

    Time frame: Baseline, Week 14

Other outcomes

  1. Change From Baseline for Other Biochemical Markers of Cholestasis: Total Cholesterol, Low Density Lipoprotein Cholesterol

    Total cholesterol (TC) level and low density lipoprotein cholesterol (LDLC) level were considered as biochemical markers of cholestasis.

    Time frame: Baseline, Week 14

07

Results

Posted Apr 12, 2017

Participant flow

The study was conducted in 8 centers in Great Britain, Canada, and the United States between 22 April 2014 and 12 February 2016.

Participant flow — Overall Study
MilestoneMaralixibat (LUM001)
Started27
Down-titrated on lum001 during the study5
Completed23
Not completed4
Withdrew: Adverse event2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An Adverse Event (AE) was defined as any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. TEAEs were AEs with a start date on or after the first dose of investigational product and started prior to the last dose of investigational product plus 14 days.

Time frame:
From start of study drug administration until Week 18
Reported as:
Number · participant
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
participantMaralixibat (LUM001) 1 mgMaralixibat (LUM001) 2.5 mgMaralixibat (LUM001) 5 mgMaralixibat (LUM001) 7.5 mgMaralixibat (LUM001) 10 mg
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)122119
PrimaryChange From Baseline in Fasting Serum Bile Acid Level at Week 14

Serum bile acid levels were evaluated using blood samples collected.

Time frame:
Baseline, Week 14
Reported as:
Mean · micromoles per liter
Change From Baseline in Fasting Serum Bile Acid Level at Week 14
micromoles per literMaralixibat (LUM001)
Baseline38.941 ± 38.6614
Change From Baseline-14.841 ± 31.3709
Statistical analysis
  • Maralixibat (LUM001) · Wilcoxon's signed rank test · p = 0.0043 · Mean difference (net): -14.841 · 95% CI -27.251 to -2.432
SecondaryChange From Baseline in Liver Enzyme Levels in Serum

Levels of liver enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) in serum were evaluated.

Time frame:
Baseline, Week 14
Reported as:
Mean · units per liter (U/L)
Change From Baseline in Liver Enzyme Levels in Serum
units per liter (U/L)Maralixibat (LUM001)
ALT: Baseline108.5 ± 78.95
ALT: Change From Baseline10.5 ± 63.07
AST: Baseline88.3 ± 43.70
AST: Change From Baseline11.7 ± 34.14
ALP: Baseline471.6 ± 316.93
ALP: Change From Baseline36.7 ± 170.87
SecondaryChange From Baseline in Bilirubin Levels at Week 14

Total Bilirubin and Direct (Conjugated) Bilirubin levels were evaluated.

Time frame:
Baseline, Week 14
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Baseline in Bilirubin Levels at Week 14
milligram per deciliter (mg/dL)Maralixibat (LUM001)
Total Bilirubin Level: Baseline1.22 ± 0.775
Total Bilirubin Level: Change From Baseline0.24 ± 0.666
Conjugated Bilirubin Level: Baseline0.60 ± 0.510
Conjugated Bilirubin Level: Change From Baseline0.19 ± 0.450
SecondaryChange From Baseline in Pruritus as Measured by Adult Itch Reported Outcome (ItchRO) Weekly Sum Score

The Adult ItchRO instrument was completed twice daily using an electronic diary (eDiary). Each morning and evening score had a range from 0-10, with the higher score indicating increasing itch severity. The following was used for assessing the Adult ItchRO daily score: The score which represented the most severe itching for the day (morning or evening) was taken for each day as the daily score (maximum daily score of 10); If only 1 of the 2 scores was available for the day, the score that was available was used as the daily score; If both the morning and the evening scores were missing, the score was considered missing for the day.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on scale
Change From Baseline in Pruritus as Measured by Adult Itch Reported Outcome (ItchRO) Weekly Sum Score
units on scaleMaralixibat (LUM001)
Baseline15.00 ± 18.735
Change From Baseline-7.67 ± 16.326
Other pre-specifiedChange From Baseline for Other Biochemical Markers of Cholestasis: Total Cholesterol, Low Density Lipoprotein Cholesterol

Total cholesterol (TC) level and low density lipoprotein cholesterol (LDLC) level were considered as biochemical markers of cholestasis.

Time frame:
Baseline, Week 14
Reported as:
Mean · mg/dL
Change From Baseline for Other Biochemical Markers of Cholestasis: Total Cholesterol, Low Density Lipoprotein Cholesterol
mg/dLMaralixibat (LUM001)
TC Level: Baseline213.0 ± 50.62
TC Level: Change From Baseline-21.2 ± 25.46
LDLC Level: Baseline121.4 ± 40.52
LDLC Level: Change From Baseline-16.3 ± 17.64

Adverse events

Collected over From start of study drug administration up to follow up (Week 18). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maralixibat (LUM001)—4/27 (14.8%)25/27 (92.6%)
Most frequent serious events
Most frequent serious events
EventMaralixibat (LUM001)
MelaenaGastrointestinal disorders1/27
Upper gastrointestinal haemorrhageGastrointestinal disorders1/27
AppendicitisInfections and infestations1/27
Joint dislocationInjury, poisoning and procedural complications1/27
CholangitisHepatobiliary disorders1/27
Most frequent other events
Showing 10 of 17
Most frequent other events
EventMaralixibat (LUM001)
DiarrhoeaGastrointestinal disorders14/27
NauseaGastrointestinal disorders9/27
Abdominal painGastrointestinal disorders8/27
HeadacheNervous system disorders6/27
Abdominal distensionGastrointestinal disorders4/27
FatigueGeneral disorders4/27
ArthralgiaMusculoskeletal and connective tissue disorders3/27
Abdominal discomfortGastrointestinal disorders3/27
Muscle spasmsMusculoskeletal and connective tissue disorders2/27
Neck painMusculoskeletal and connective tissue disorders2/27

Baseline characteristics

Safety population included all participants who received at least 1 dose of the investigational product.

Age, Continuous
Age, Continuous(Years)Maralixibat (LUM001)
Mean43.7 ± 11.35
Sex: Female, Male
Sex: Female, Male(Participants)Maralixibat (LUM001)
Female9
Male18
08

Study locations

9 sites
  • Scripps Clinic
    La Jolla, California 92037, United States
  • University of California at Davis
    Sacramento, California 95817, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • University of Calgary Liver Unit
    Calgary, Alberta T2N 4Z6, Canada
  • University Health Network, Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • University of Birmingham
    Birmingham, England B15 2TT, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2014
First posted
Feb 13, 2014
Start
Mar 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Apr 12, 2017
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02061540
Responsible party
Sponsor
First posted
Feb 13, 2014
Start date
Mar 2014
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Apr 12, 2017
Last update
Mar 29, 2019

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion